Apalutamide, added to standard treatment with androgen deprivation therapy (ADT), provides comparable clinical benefits among Asian vs non-Asian patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a subset analysis of the phase III SPARTAN study.
Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.
Beta blockers and/or renin-angiotensin inhibitors appear to be useful for preventing cardiotoxicity from anthracycline exposure, according to the results of a systematic review and meta-analysis presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.
Despite good attitudes toward breast self-examination, being well-informed about the procedure may still not translate to improvements in practice among female healthcare workers, reports a Philippine study presented at the recently concluded European Society for Medical Oncology (ESMO) Asia 2018 Congress.
Administration of the RANKL* inhibitor denosumab prior to chemotherapy initiation may prevent secondary reduction in bone mineral density (BMD) induced by chemotherapy, according to the ESPRESSO-02 study presented at ESMO Asia 2018.
In the era of Highly Active Antiretroviral Therapy (HAART), majority of the malignancies in AIDS patients are non-AIDS-defining cancers (NADC), according to an India study presented at the recently concluded European Society for Medical Oncology Asia 2018 Congress (ESMO Asia 2018).
There appears to be an increased risk of arterial thromboembolism (aTE) in patients with pancreatic cancer undergoing palliative chemotherapy, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.
Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïveRET-mutated (RETmut) medullary thyroid cancer (MTC) patients.